Marín-Jiménez Ignacio, Carrascosa José Manuel, Guigini Marcelo Alejandro, Monte-Boquet Emilio
Inflammatory Bowel Disease UNIT, Centro de Enfermedades Inflamatorias Mediadas por la Inmunidad, Gastroenterology Department, Instituto de Investigación Sanitaria Gregorio Marañón, Hospital Universitario Gregorio Marañón, Madrid. España..
Dermatology Department, Hospital Universitario Germans Trias i Pujol, Badalona (Barcelona). España..
Farm Hosp. 2021 Jul 7;45(5):240-246.
To analyze knowledge, perceptions, attitude, barriers and facilitators of biosimilars uptake across physicians managing immune diseases and hospital pharmacists.
Two structured and closed anonymous online surveys were designed and sent to 41 physicians (rheumatologists, dermatologists, gastroenterologists) and 32 hospital pharmacists. Sociodemographic and clinical practice related variables were collected. We also gathered information about biosimilars knowledge and importance, access, attitude in clinical practice and perceptions, barriers and facilitators to biosimilars uptake. A descriptive analysis was performed.
Surveys response rate was 100% (hospital pharmacists) and 96% (physicians). We found certain lack of biosimilars knowledge about key aspects including switching, extrapolation, interchangeability or substitution. There was a great variability in the types and brands of biosimilars depending on the hospital. We observed several organization preferences, policies, and practices regarding biosimilars. General perception and attitude to biosimilars was positive. If used, biosimilars were predominantly prescribed in biologic treatment-naive patients (this indication was considered adequate and participants felt comfortable with it). Reluctance to switch in clinical practice was common. The main barriers to biosimilars uptake were the lack of confidence and knowledge. The main facilitators were the development of recommendations from professional associations and societies and the demonstration of interchangeability efficacy. We gathered concerns about biosimilar long term efficacy and safety, lack of real-life data, lack of biosimilars traceability or the risk of biologic reference medicines stock shortages.
Biosimilar education and more evidence filling current gaps might help increase prescriber knowledge, comfort and use of biosimilars.
分析治疗免疫疾病的医生和医院药剂师在生物类似药使用方面的知识、认知、态度、障碍及促进因素。
设计了两份结构化、封闭式匿名在线调查问卷，并发送给41名医生（风湿病学家、皮肤科医生、胃肠病学家）和32名医院药剂师。收集了社会人口统计学和临床实践相关变量。我们还收集了有关生物类似药知识及其重要性、获取途径、临床实践中的态度以及生物类似药使用的认知、障碍和促进因素的信息。进行了描述性分析。
调查回复率为100%（医院药剂师）和96%（医生）。我们发现，在包括换药、外推、可互换性或替代等关键方面，对生物类似药的知识存在一定欠缺。不同医院的生物类似药类型和品牌差异很大。我们观察到了有关生物类似药的几种组织偏好、政策和做法。对生物类似药的总体认知和态度是积极的。如果使用生物类似药，主要用于未接受过生物治疗的患者（这一适应症被认为是合适的，参与者对此感到放心）。临床实践中普遍不愿换药。生物类似药使用的主要障碍是缺乏信心和知识。主要促进因素是专业协会和学会制定的建议以及可互换性疗效的证明。我们收集到了对生物类似药长期疗效和安全性的担忧、缺乏实际数据、生物类似药缺乏可追溯性或生物参比药品库存短缺的风险。
生物类似药教育以及填补当前空白的更多证据可能有助于增加开处方者对生物类似药的知识、信心并促进其使用。
